May 6, 2021
Hospira recalls one lot each of 0.5% Bupivacaine and 1% Lidocaine because of mislabeling
Editor's Note
Hospira Inc, a Pfizer company, announced May 4 that it is recalling lot EG6023 of 0.5% Bupivacaine Hydrochloride Injection, USP 30 mL and lot EG8933 of 1% Lidocaine HCL Injection, USP 30 mL because of mislabeling.
A portion of each lot was incorrectly labeled as the other product. The issue was identified by a customer.
Use of the impacted products could cause adverse events of moderate to high severity.
Free Daily News
- CDC communication breakdown raises public health risk
- Study: Shorter radiation schedule matches safety of standard prostate cancer treatment
- Poll: Healthcare cybersecurity leaders overlook AI-enabled physical security gaps
- ASC improves hospital efficiency, maintains outcomes despite higher-acuity joint replacement patients
- Hospital support staff cuts raise risk of infection, delays in care
- Study: Blocking stress-linked prolactin surge relieves postoperative pain in women
- Report ranks states by nursing opportunity
- Report: Hospitals double down on ASCs as outpatient shift accelerates
- Centralized waitlists slash joint replacement wait times in Canada, study shows
- Airborne bacteria pose hidden threat in cardiac ORs, study warns
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement